Ann: Regeneus and AGC collaborate on Progenza in Japan, page-16

Issuer Name Regeneus Ltd
Industry Group: Biotechnology
Share on Issue 208,885,143
Market Cap 36,554,900

Could be the next NOX, their product Kvax is a novel Cancer vaccine technology that uses a dog's own
tumour cells as a source of therapy. Regeneus Report value it at 52c per share http://regeneus.com.au/media/analyst_reports/14_09_Edison_Coverage.pdf
Regeneus Limited (RGS) is a Sydney based regenerative medicine company founded
in August 2007 that is focused on using the regenerative capacities of
adipose-derived cells to develop cell therapies for humans and animals.
Regenerative medicine is a rapidly growing multidisciplinary speciality that is
focused on the repair or regeneration of cells, tissues and organs. The primary
goal is to enhance the body's natural ability to replace tissue damaged or
destroyed by injury or disease. The Group has two operating segments: Human
Health and Veterinary Health.

HUMAN HEALTH: HiQCell is a personalised (autologous) adipose (fat) derived stem
cell therapy for human osteoarthritis and other musculoskeletal conditions.
HiQCell is a simple, same day medical procedure supervised by a Regeneus
licensed treating medical practitioner (TMP).

ANIMAL HEALTH: CryoShot is an allogeneic adipose-derived stem cells to treat
canine and equine osteoarthritis. One in five dogs suffer from osteoarthritis,
with no current cure. The current treatment options are generally
anti-inflammatories, which have a short term impact and can have side effects.
CryoShot targets a longer term and more effective pain management market for
dogs and horses. Kvax is a novel cancer vaccine technology that uses a dog's own
tumour cells as a source of therapy.